MZT2B (mitotic spindle organizing protein 2B) is a centrosomal protein essential for recruiting and assembling the gamma-tubulin ring complex (gTuRC) at the centrosome 12. The gTuRC nucleates microtubule formation by regulating minus-end polymerization of alpha-beta tubulin heterodimers, a critical process for centrosome duplication and mitotic spindle assembly 2. Beyond its canonical mitotic function, MZT2B exhibits oncogenic properties in multiple cancer types. In non-small cell lung cancer (NSCLC), MZT2B is significantly upregulated and promotes malignant phenotypes by enhancing mitochondrial oxidative phosphorylation through COX5B regulation, driving cell proliferation and invasion 3. MZT2B overexpression in gastric cancer correlates with advanced disease, lymph node metastasis, and poor prognosis 4, and is identified as a molecular subtype marker in meningiomas 5. Additionally, MZT2B expression is elevated in intraluminal blood of intracranial aneurysms and positively correlates with peripheral blood expression, suggesting disease-mediated transcriptional changes 6. In hepatocellular carcinoma, MZT2B co-expresses with NEDD1 in immunosuppressive macrophage subsets, potentially influencing tumor progression and immunotherapy response 7. These findings position MZT2B as both a centrosomal architecture protein and an emerging cancer-associated biomarker with therapeutic implications.